ClinicalTrials.gg
RecruitingNCT06067841Updated Aug 10, 2026

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 1 interventional study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 15 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 1 of them phase 3. Prostatic Neoplasms · Bristol-Myers Squibb.

Planned enrollment
10th of 29
140 · median 94
Started
2023
the only one that year
Phase 1
10 of 30
1 open now
Registered
28th of 30
by date

Among the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, this one is the 10th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2023, is one of 10 in phase 1, and was the 28th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Prostatic Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Keywords

  • Prostate Cancer
  • Castration-resistant prostate cancer
  • Adenocarcinoma of the prostate
  • Prostatic Neoplasms Castration-Resistant
  • Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have or cytologically confirmed adenocarcinoma of the prostate.
  • Participant must have an (ECOG) performance status 0 to 1.
  • Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
  • Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

Exclusion criteria

Exclusion Criteria:

  • Participant must not have history of .
  • Participant must not have impaired cardiac function or cardiac disease.
  • Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Administration of BMS-986460

    Drug: BMS-986460

Interventions

  • DrugBMS-986460

    Specified dose on specified days.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 112 weeks

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 112 weeks

  3. Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteria

    Time frame: Up to 28 days

  4. Number of participants with AEs leading to study intervention discontinuation

    Time frame: Up to 104 weeks

  5. Number of deaths

    Time frame: Up to 108 weeks

Secondary outcomes

  1. Maximum concentration (Cmax)

    Time frame: Up to 13 weeks

  2. Time of maximum concentration (Tmax)

    Time frame: Up to 13 weeks

  3. Area under the plasma concentration-time curve (AUC)

    Time frame: Up to 13 weeks

  4. Number of participants with a confirmed prostate specific antigen decline of ≥ 30% from baseline response rate

    Time frame: Up to 108 weeks

  5. Number of participants with soft tissue response

    Time frame: Up to 108 weeks

  6. Duration of response (DOR)

    Time frame: Up to 108 weeks

07

Study locations

10 of 15 sites recruiting
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
    Recruiting
    • Sandhya Srinivas, Site 0004 · Contact650-725-2078
  • Florida Cancer Specialists Sarasota Drug Development Unit
    Sarasota, Florida 34232, United States
    Recruiting
    • Manish Patel, Site 0007 · Contact941-377-9993
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Atish Choudhury, Site 0003 · Contact000-000-0000
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Dana Rathkopf, Site 0002 · Contact646-422-4379
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
    Recruiting
    • Andrew Armstrong, Site 0001 · Contact919-668-8797
  • Local Institution - 0006
    San Antonio, Texas 78229, United States
    Withdrawn

    Not enrolling at this site.

  • NEXT Oncology
    San Antonio, Texas 78229, United States
    Recruiting
    • David Sommerhalder, Site 0008 · Contact210-580-9500
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
    • Ruben Raychaudhuri, Site 0005 · Contact206-618-8002
  • Local Institution - 0009
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
    • Site 0009 · Contact
  • Local Institution - 0011
    Montreal, Quebec H2X 0A9, Canada
    Not yet recruiting
    • Site 0011 · Contact
  • Local Institution - 0018
    Bordeaux, Aquitaine 33076, France
    Not yet recruiting
    • Site 0018 · Contact
  • Centre Leon Berard
    Lyon Cedex08, Auvergne-Rhône-Alpes 69373, France
    Recruiting
    • Armelle Vinceneux, Site 0013 · Contact33426556833
  • Institut Paoli-Calmettes
    Marseille, Nan 13009, France
    Recruiting
    • Gwenaelle Gravis, Site 0019 · Contact33491223894
  • Gustave Roussy
    Villejuif, Val-de-Marne 94800, France
    Recruiting
    • Christophe Massard, Site 0014 · Contact+33142114211
  • Local Institution - 0017
    Paris, 75015, France
    Not yet recruiting
    • Site 0017 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Aug 2029, 70 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 70 months is above that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 5, 2023
StartActual
Oct 18, 2023
Primary completionEst.
Aug 24, 2029
CompletionEst.
Jul 27, 2031
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06067841
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Oct 18, 2023
Primary completion
Aug 24, 2029 (estimated)
Completion
Jul 27, 2031 (estimated)
Last update
Aug 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion